Shanghai Huarao Industrial

Zhao Chao, Executive Director of Shanghai Huarao Industrial and President of Buchang Pharmaceuticals, handles day-to-day investment operations. His father, Zhao Tao, serves as the ultimate decision-maker and beneficial owner, reflecting a patriarchal governance structure common among Chinese family-controlled investment vehicles.

The firm operates as a corporate investor rather than a formal single-family office. Its capital comes directly from the Zhao family's controlling stake in Shandong Buchang Pharmaceuticals, and its investment activities are managed alongside — not separately from — the operating business. There is no evidence of external LP capital or multi-family office services.

Shanghai Huarao Industrial is the investment vehicle for the Zhao family, who control Buchang Pharmaceuticals. Zhao Tao founded both the pharmaceutical company and the investment arm; his son Zhao Chao holds senior roles in both entities. The investment firm's deal flow often complements Buchang's core drug development and distribution business.

The firm primarily targets healthcare services and pharmaceutical ventures, reflecting the family's operating expertise. It also pursues general technology investments across early to expansion stages. Confirmed investment activity spans seed-stage, startup, and late-stage venture rounds within China.

Public records suggest the firm deploys exclusively proprietary family capital. There is no evidence of fundraising from external limited partners or structured co-investment programs. Investments appear to be made directly from the Zhao family balance sheet.